Literature DB >> 27060876

Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score.

A Kumar1, S Kedia1, H Sharma1, S R Gamanagatti2, G S Gulati3, B Nayak1, B Thakur4, S K Acharya1.   

Abstract

BACKGROUND: Results of endovascular interventions in hepatic venous outflow tract obstruction (HVOTO) have been reported from limited studies. Treatment outcomes and prognostic scores need further validation. AIM: To evaluate treatment outcomes and prognostic scores for hepatic venous outflow tract obstruction in an Indian population.
METHODS: Consecutive patients with hepatic venous outflow tract obstruction diagnosed at a tertiary centre were included. Technical success and clinical response after endovascular interventional therapy were documented. Predictors of survival were assessed with Cox-proportional model. A new score was derived from the factors significant on multivariate analysis and compared with Child-Turcotte-Pugh, model for end-stage liver disease (MELD), Rotterdam prognostic index (PI) and Budd-Chiari syndrome-transjugular intrahepatic portosystemic shunt ( BCS-TIPSS) PI.
RESULTS: Three hundred and thirty-four patients (56.6% males), median age 24 (3-62) years were included. Hepatic vein was the commonest site of block-isolated hepatic vonous block in 48%, combined hepatic venous-inferior vena cava block in 46%. Endovascular interventional therapy was performed in 233/334 (70%) with 90% technical success. Clinical response was complete in 166 (71.2%), partial in 58 (24.9%) and no response in nine (3.9%). Majority of cases with HV block did not require TIPSS and could be treated with angioplasty (with/without stenting). On Cox-proportional multivariate analysis, Child class C and response to intervention were independent predictors of outcome and used to derive the All India Institute of Medical Sciences (AIIMS) hepatic venous outflow tract obstruction score. The 5-year survival was 92% (95% CI, 81-97%) for score ≤3, 79% (95%CI, 63-88%) for score >3 and ≤4, and 39% (95% CI, 21-57%) for score >4. The performance of AIIMS hepatic venous outflow obstruction score was superior to other prognostic indices.
CONCLUSIONS: Advanced Child class and no response to intervention are associated with poor outcomes. The All India Institute of Medical Sciences hepatic venous outflow tract obstruction score predicts survival better than other prognostic scores.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27060876     DOI: 10.1111/apt.13604

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Budd Chiari Syndrome and Intrahepatic Cholangiocarcinoma, An Unusual Combination: Case Report and Review of the Literature.

Authors:  Anshuman Elhence; Shivanand Gamanagatti; Prasenjit Das
Journal:  Perm J       Date:  2020-11

Review 2.  Budd-Chiari syndrome/hepatic venous outflow tract obstruction.

Authors:  Dominique-Charles Valla
Journal:  Hepatol Int       Date:  2017-07-06       Impact factor: 6.047

Review 3.  Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis.

Authors:  Anil C Anand; Bhaskar Nandi; Subrat K Acharya; Anil Arora; Sethu Babu; Yogesh Batra; Yogesh K Chawla; Abhijit Chowdhury; Ashok Chaoudhuri; Eapen C Eapen; Harshad Devarbhavi; RadhaKrishan Dhiman; Siddhartha Datta Gupta; Ajay Duseja; Dinesh Jothimani; Dharmesh Kapoor; Premashish Kar; Mohamad S Khuroo; Ashish Kumar; Kaushal Madan; Bipadabhanjan Mallick; Rakhi Maiwall; Neelam Mohan; Aabha Nagral; Preetam Nath; Sarat C Panigrahi; Ankush Pawar; Cyriac A Philips; Dibyalochan Prahraj; Pankaj Puri; Amit Rastogi; Vivek A Saraswat; Sanjiv Saigal; Akash Shukla; Shivaram P Singh; Thomas Verghese; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2020-04-28

4.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

5.  Timing of Transjugular Intrahepatic Portosystemic Stent-shunt in Budd-Chiari Syndrome: A UK Hepatologist's Perspective.

Authors:  Faisal Khan; Homoyon Mehrzad; Dhiraj Tripathi
Journal:  J Transl Int Med       Date:  2018-10-09

6.  Outcomes of endovascular interventional therapy for primary Budd-Chiari syndrome caused by hepatic venous obstruction.

Authors:  De-Lei Cheng; Nan Zhu; Hao Xu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-09-07       Impact factor: 2.447

Review 7.  State of the Art, Current Perspectives, and Controversies of Budd-Chiari Syndrome: A Review.

Authors:  Paschalis Gavriilidis; Gabriele Marangoni; Jawad Ahmad; Daniel Azoulay
Journal:  J Clin Med Res       Date:  2022-04-30

Review 8.  An Update on the Management of Budd-Chiari Syndrome.

Authors:  A Sharma; S N Keshava; A Eapen; E Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2020-07-20       Impact factor: 3.199

9.  Behcet's Disease With Budd-Chiari Syndrome and Challenges in Its Management.

Authors:  Sudheer K Vuyyuru; Shivanand Gamanagatti
Journal:  ACG Case Rep J       Date:  2020-03-19

Review 10.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.